Hepatitis
C Top News Articles |
|
 Insulin
Resistance and Diabetes Increase the Risk of Liver
Fibrosis and Hepatocellular Carcinoma in People with Chronic Hepatitis
C
- 6/24/08 |
 Sustained
Response to Interferon-based Therapy Reduces
the Likelihood of Type 2 Diabetes
- 6/24/08 |
 Aspirin
(Acetylsalicylic Acid) Inhibits HCV Replication
in Laboratory Study - 6/20/08 |
 Course
of Chronic
Hepatitis C in Children -
6/17/08 |
| Study
Review Confirms High Cure Rate for Acute Hepatitis C,
but Treatment Dilemma Persists - 6/17/08 |
 Vertex
Reports Encouraging Data from PROVE3 Trial of HCV Protease Inhibitor
Telaprevir (VX-950) -
6/13/08 |
 Pegylated
Interferon plus Ribavirin for 48 Weeks is Superior to 24 Weeks for
Patients with HCV Genotype 6 - 6/13/08 |
 Association
between Hepatitis B and C Virus Infection
and Extrahepatic Bile Duct Cancer - 6/13/08
|
 Selected
Hepatitis C Patients with Decompensated Cirrhosis
Can Benefit from Interferon-based Therapy
prior to Liver Transplantation -
6/10/08 |
 Herbal
Product Stevioside Inhibits HCV Replication and Curcumin Suppresses
Fibrogenic Cell Activity in Laboratory Studies -
6/10/08 |
 Active
and Recovering Injection Drug Users Can Benefit
from Hepatitis C Treatment if They Maintain Good Adherence -
6/10/08 |
| InterMune
and Anadys Begin Phase 1 Clinical Trials of Experimental HCV Therapies ITMN-191
and ANA598 -
6/06/08 |
 Mortality
Due to Hepatitis C in the U.S.: Has the Worst Passed? -
6/06/08 |
 Marijuana
Use Sparks Liver Transplant Controversy
-
6/06/08 |
 Chronic
Hepatitis C May Contribute to an Elevated Risk of Bone
Fractures in Postmenopausal Women -
6/03/08 |
| Sustained
Virological Response to Pegylated Interferon Alfa-2b
(PegIntron) with or without Ribavirin Predicts Continued Response through
5 Years -
5/30/08 |
| Very
Early Response to Interferon-based Therapy
for Hepatitis C Is Apparent within the First 24 Hours -
5/30/08 |
| Schering
Plough Initiates Phase 3 Studies with Experimental Oral HCV Protease Inhibitor
Boceprevir in Treatment-naive HCV Patients
and in Those Who Failed Prior Treatment -
5/23/08 |
| Significance
of Transient HCV Viral Load "Blips" during Interferon-based
Therapy for Chronic Hepatitis C -
5/23/08 |
| Safety
and Activity of Once-Monthly Albinterferon Alfa-2b (Albuferon)
in Genotype 2/3 Chronic Hepatitis C Patients -
5/23/08 |
| Antiviral
Activity, Pharmacodynamics, and Quality of Life in Genotype 1 Hepatitis C Patients
Treated with Albinterferon (Albuferon)
- 5/23/08 |
| Response
to Controlled-release Interferon Alfa-2b (Locteron)
in Genotype 1 Hepatitis C Patients -
5/23/08 |
| Symptoms
and Response to Interferon plus Ribavirin in Children with Chronic Hepatitis C
- 5/23/08 |
| Response
to Interferon-based Therapy in Hispanic Patients
with Chronic Hepatitis C -
5/20/08 |
| Platelet
Count Is a Strong Predictor of Sustained Response to Pegylated
Interferon/ribavirin in Prior Non-Responders (EPIC 3) -
5/20/08 |
| Amino
Acid Substitutions in HCV Core Region Predict Poor Response to Pegylated
Interferon/ribavirin in Genotype 1b Patients -
5/20/08 |
| HCV
May Inhibit HBV Replication in HCV-HBV Coinfected Patients -
5/20/08 |
| FibroScan
Liver Stiffness Measurement Distinguishes Fast and Slow Fibrosis Patterns after
Liver Transplantation -
5/16/08 |
| Incidence
of and Risk Factors for Hepatocellular Carcinoma
in Hepatitis C Patients with Advanced Liver Disease: HALT-C Trial -
5/16/08 |
| Sorafenib
(Nexavar) Improves Outcomes in Patients with Hepatocellular
Carcinoma -
5/16/08 |
| Rapid
Virological Response Is a Stronger Predictor than HCV Genotype of Sustained Response
to Interferon-based Therapy -
5/13/08 |
| Experimental
HCV Protease Inhibitor TMC435350 Demonstrates
Promising Activity and Tolerability in Early Clinical Trial -
5/13/08 |
| Mitochondrial
Antioxidant Mitoquinone (MitoQ) May Reduce Liver Necroinflammation in Patients
with Chronic Hepatitis C -
5/13/08 |
| Taribavirin
Efficacy Similar to Ribavirin in Combination
Therapy for Hepatitis C, but with Less Anemia -
5/09/08 |
| Natural
History of HCV-Related Cirrhosis after Liver
Transplantation -
5/09/08
|
| Pegylated
Interferon plus Ribavirin Is Effective for Patients with HCV-HBV Coinfection
- 5/09/08
|
| Factors
Predicting Relapse in Patients with Genotype 2/3 HCV Treated with Pegylated
Interferon plus Ribavirin -
5/06/08 |
| Nitazoxanide
Added to Standard Therapy Improves Response in Patients with Genotype
4 HCV: STEALTH C-1 Study -
5/06/08 |
| Cyclophilin
Inhibitor Debio 025 Exhibits Additive Activity against HCV in Combination
with Pegylated Interferon -
5/06/08 |
| Boceprevir
Added to Pegylated Interferon/Ribavirin Increases
Sustained Response in Treatment-naive Patients and Some Prior Non-responders
-
4/29/08 |
| HCV
Polymerase Inhibitor R1626 Produces Good Response with Pegylated
Interferon/Ribavirin and Has High Barrier to Resistance -
4/29/08 |
| R7128
Demonstrates Potent Anti-HCV Activity in Combination
with Pegylated Interferon/Ribavirin; Ongoing Trial to be Expanded
-
4/29/08 |
| Large
HCV RNA Decrease Reduces Adverse Clinical Outcomes, but Pegylated
Interferon Maintenance Adds Little Benefit (HALT-C) -
4/29/08 |
| European
Association for the Study of the Liver (EASL) Meeting Opens in Milan -
4/24/08 |
| Telaprevir
plus Pegylated Interferon and Ribavirin Allows Shorter Therapy for
Patients with Genotype 1 HCV -
4/24/08 |
| Pegylated
Interferon Maintenance Demonstrates Benefits for Hepatitis C Patients
with Portal Hypertension -
4/24/08 |
| Limitations
of an 8-week Course of Pegylated interferon plus Ribavirin
for Genotype 2 Hepatitis C Patients with Rapid Virological Response -
4/24/08 |
| ViroPharma
and Wyeth Halt Development of HCV-796 for
Hepatitis C -
4/24/08 |
| Factors
Predicting Response to Therapy for Chronic Hepatitis C -
4/15/08 |
| Liver
Gene Expression Predicts Response to Pegylated Interferon
plus Ribavirin -
4/15/08 |
| Combination
Therapy Improves Survival Time for Patients with Advanced Liver Cancer
-
4/11/08 |
| Deaths
Due to Hepatitis C Have Increased Dramatically over the Past Decade -
4/04/08 |
| InterMune
Presents Top-line Results from Phase 1b Trial of HCV Protease
Inhibitor ITMN-191 Monotherap -
4/04/08 |
| Rates
of Hepatitis A and B Have Decreased Dramatically since 1990, but Drop in Hepatitis
C Has Leveled Off -
4/01/08 |
| Valeant
Reports Promising 12-week Phase IIb Data on Taribavirin
-
4/01/08 |
| In
Vivo Experimental HCV Vaccine Shows Promise,
but Dynavax/Merck HBV Vaccine Candidate Put on Hold Due to Safety Concerns
-
4/01/08 |
| New
Network Will Send Drug Alerts Instantly to U.S. Doctors via Email -
4/01/08 |
| FDA
Approves New Weight-Based Dosing Regimen for PegIntron
plus Ribavirin -
3/28/08 |
| Alcohol,
Tobacco, and Cannabis All May Promote Liver Disease Progression in People with
Chronic Hepatitis C -
3/28/08 |
| Adiponectin
Level Predicts Liver Steatosis and Response to Interferon-based
Treatment for Chronic Hepatitis C -
3/21/08 |
|
FDA-approved
Treatments
